BiotechTube
DalCor Pharmaceuticals

DalCor Pharmaceuticals

Montreal, United States· Est.
dalcorpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

DalCor Pharmaceuticals is a clinical-stage biotech developing dalcetrapib, a precision cardiovascular drug for post-heart attack patients with the ADCY9 AA genotype, representing approximately 20% of the global population. The company is advancing the drug into the Dal-GenE-2 (DAL-302) Phase 3 confirmatory trial based on promising Phase 3 data from the dal-GenE study, which showed a significant reduction in myocardial infarction risk. DalCor holds an exclusive worldwide license for dalcetrapib and its associated genetic marker, and has partnered with Roche on a companion diagnostic. The company is led by an experienced management team with deep cardiovascular and pharmaceutical industry expertise.

Cardiovascular

Technology Platform

Precision pharmacogenetic approach targeting the ADCY9 AA genotype for cardiovascular therapy, supported by a companion diagnostic.

Funding History

2
Total raised:$150M
Series B$100M
Series A$50M

Opportunities

Success would establish the first precision pharmacogenetic medicine in cardiovascular disease, addressing a major unmet need in a large, genetically-defined patient subgroup (~20% of global population).
The higher genotype prevalence in populations with African ancestry offers a significant opportunity to address health disparities and tap into an underserved market.

Risk Factors

The company faces extreme binary risk as its entire value hinges on the success of a single Phase 3 trial for its only asset.
Regulatory and commercial adoption risks are high due to the novel precision medicine approach in cardiology, which requires companion diagnostic testing and a shift in treatment paradigms.

Competitive Landscape

DalCor's approach is unique; if successful, it would create a new niche of genotype-specific secondary prevention in cardiology with no direct competitors. However, it broadly competes with the entire market of post-ACS standard-of-care therapies (statins, antiplatelets, etc.) and must demonstrate superior value in its target population. Other CETP inhibitors have largely failed in development.

More companies in Small Molecule Drugs →More companies in United States →